VCM
IBRX icon

Voleon Capital Management’s ImmunityBio IBRX Stock Holding History

Voleon Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.81M Sell
549,126
-608,032
-53% -$4.6M 0.09% 226
2026
Q1 		$8.88M Sell
1,157,158
-357,428
-24% -$2.45M 0.19% 119
2025
Q4 		$3M Buy
1,514,586
+1,498,332
+9,218% +$3.39M 0.06% 282
2025
Q3 		$40K Buy
+16,254
New +$41.9K ﹤0.01% 876

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Voleon Capital Management's IBRX Position: Q2 2026 in Review

Voleon Capital Management reduced its ImmunityBio (IBRX) stake by 53% in Q2 2026, selling an estimated $4.6M and leaving 549,126 shares worth $4.81M. The position accounts for 0.09% of the portfolio, ranked #226.

Voleon Capital Management first reported a position in IBRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $8.88M in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Voleon Capital Management held 549,126 shares of ImmunityBio worth $4.81M as of Q2 2026.
  • Voleon Capital Management sold 608,032 ImmunityBio shares in Q2 2026, an estimated $4.6M.
  • ImmunityBio made up 0.09% of Voleon Capital Management's portfolio in Q2 2026, its #226 holding.
  • Voleon Capital Management first reported a position in ImmunityBio in Q3 2025 and has held it in 4 quarters since.
  • Voleon Capital Management's ImmunityBio position peaked at $8.88M in Q1 2026.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.